PDCD1 and nasopharyngeal carcinoma: Cadonilimab, a bispecific antibody targeting PD-1 and CTLA-4, has shown clinical activity with an ORR of 68% when combined with chemotherapy, which is similar to the standard anti-PD-1-platinum chemo combination, in patients with PD-1-refractory R/M NPC [43].